Many thanks to those that completed surveys about their experiences living with Psoriatic Arthritis and Ankylosing Spondylitis. Your input helped us develop submissions to the Canadian Agency for Drugs and Technologies in Health (CADTH) to consider as part of their review of bimekizumab. These submissions were part of a collaboration with the Canadian Psoriasis Network, Canadian Association of Psoriasis Patients, Canadian Spondyloarthritis Association, Creaky Joints Canada, and the Arthritis Society Canada. Over the coming months, we will be working on policy submissions in response to the consultation on the Canada Disability Benefit and Patented Medicine Prices Review Board – feel free to reach out if you have any feedback or questions we can consider when drafting these submissions.